Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Kedudukan dalam Saham #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Harga Saham
$0.25974701
Disegerakkan terakhir: 2025-01-06
Modal Pasaran
$2.04M
Perubahan (1 hari)
0.74%
Perubahan (1 tahun)
0.00%
Negara
FR
Perdagangan Acticor Biotech SAS (ALACT)

Kategori

EPS untuk Acticor Biotech SAS (ALACT)
EPS setakat June 2024 TTM: $-1.95
Menurut laporan kewangan terkini dan harga saham Acticor Biotech SAS, EPS semasa syarikat (TTM) adalah $-1.95. Pada akhir tahun 2022, syarikat mempunyai EPS sebanyak $-1.62 penurunan berbanding EPS tahun 2021 iaitu $-1.84.
Sejarah EPS untuk Acticor Biotech SAS dari 2010 hingga 2026
EPS pada akhir setiap tahun
Tahun EPS Ubah
2026 (TTM) $-1.95 -99.90%
2023 0.00 -99.90%
2022 $-1.62 -12.08%
2021 $-1.84 26.05%
2020 $-1.46 35.69%
2019 $-1.08 -51.93%
2018 $-2.24 -40.33%
2017 $-3.76 2,449.69%
2016 $-0.15 -66.91%
2015 $-0.45 26.87%
2014 $-0.35 -143.25%
2013 $0.81 -9.55%
2012 $0.90 35.87%
2011 $0.66 462.35%
2010 $0.12 0.00%
EPS untuk syarikat atau pesaing yang serupa
Syarikat EPS Perbezaan EPS Negara
$17.32 -986.39%
US
$27.74 -1,519.65%
NL
$-5.29 170.73%
AU
$-7.98 308.39%
US
- -
CH